Vision Loss in ARMD

globe anatomy
anatomy of the eye (click on image to enlarge)

Why am I losing vision despite treatment for age-related macular degeneration?

            Age-related macular degeneration (ARMD) is the most common cause of visual loss in older Americans.  Vision may be lost from dry-type or wet-type ARMD: 

  • Dry-type macular degeneration is the most common type and involves the disintegration of the light-sensitive tissues in the macula.  Loss of vision is usually gradual in dry macular degeneration.  Small blind spots interfere with reading numbers in a row and all the letters of a word.  Over time, these blind spots usually enlarge and take away most of the central vision.  
  • Wet-type macular degeneration accounts for about 10% of all cases of ARMD.  It occurs in patients with dry-type ARMD when abnormal blood vessels grow under the macula and cause fluid leakage, bleeding, and scarring of the macula.  Vision loss may be rapid and severe.  Straight lines may appear distorted and the central vision appears blurred early in wet-type ARMD.  Over time, a large blind spot may develop in the center of the vision.  If one eye develops wet ARMD, there is about a 50% chance the other eye will be affected within the next five years.

            There is currently no proven drug treatment to stop dry-type ARMD.  Eye vitamins are prescribed for dry-type ARMD.  However, the main purpose of the vitamins is to stave off the start of wet-type ARMD.  Although AREDS eye vitamins appear to slow the start of blind spots in the vision from dye-type AMD, they do not slow the progression of blind spots once they start. A Meditteranean diet appears to reduce the onset and progression of blind spots from dry-type macular degeneration. Therefore, it is important to limit red meat intake to once per week, eat two servings of whole fruit per day, include fish in the diet, and rely on olive oil rather than other oils with saturated fatty acids. There are a number of on-going research studies to find a treatment to slow or prevent loss of vision from dry-type ARMD.  There is even hope for treatment to reverse the loss of vision from dry-type ARMD.  Your doctor can put you in touch with study centers if you are interested in learning more about or participating in these research studies.  Age-related macular degeneration appears to be an inherited condition.  However, it may be aggravated by factors that cause hardening of the arteries like high blood pressure, high cholesterol, overweight, physical inactivity, and tobacco use.  Efforts to control these factors may be helpful in slowing loss of vision in dry-type ARMD. 

            There are fairly good treatment options for wet-type ARMD.  Injection therapy (Avastin, Lucentis, Eylea, and Beovu) is the first-line treatment for wet-type ARMD.  Lasers are second-line treatment options.  Lasers include photocoagulation (which is rarely used currently) and Visudyne photodynamic therapy.  Treatment of wet-type ARMD is effective at slowing the loss of vision.  Unfortunately, current treatments do not completely prevent the loss of vision from ARMD.  There are several reasons why patients may continue to lose vision during treatment of ARMD:

1. Insufficient treatment

Some eyes require injection therapy every four weeks to optimal effect.  If treatment is given less often, the wet-type ARMD may progress with loss of vision that may be irreversible.  This is an important reason to continue monthly injections in some eyes (as determined by the retinal specialist).  

2. Bleeding despite treatment

Bleeding under the retina from ARMD usually results in some degree of permanent scar tissue and loss of vision.  Bleeding may occur if treatment is not given frequently enough and appears more likely in patients who take blood thinners.  Blood thinners (including aspirin) are usually prescribed to prevent heart attack or stroke.  If they are prescribed, the benefits likely outweigh the risks.  However, if blood thinners are not prescribed for a patient with ARMD, they may be best avoided to reduce the risk of bleeding from ARMD.

3. Progression of dry-type ARMD while wet-type ARMD is being treated

Many patients are not aware that ARMD always starts with the dry-type.  Wet-type ARMD develops later.  Therefore, patients with wet-type ARMD may lose vision over time even though their wet-type ARMD is well controlled.  That in, they may lose vision from a worsening of dry-type ARMD over time.  Complicating this issue is the concern that the very treatment of wet-type ARMD may, in some cases, worsen the dry-type ARMD.  

4. New eye problems develop during treatment of ARMD

The ophthalmologist will look for other problems that may cause a loss of vision unrelated to ARMD.  Common causes of vision loss include cataract, which is treatable with surgery.  Other problems include glaucoma, retinal vein occlusion, and diabetic retinopathy

What is to be done about the continued loss of vision? 

            There are a number of actions that may be taken in response to continued loss of vision during treatment of ARMD.  The retinal specialist will look for other causes of loss of vision and start appropriate treatment.  The frequency of treatment may be changed in response to changes in the retina.  Low vision aids (optical and electronic magnifiers) may be helpful.  Specially-trained social workers may help make changes in the household to make it easier to remain self-sufficient.  It is helpful to remember that the peripheral vision is rarely taken by ARMD.  Therefore, although a patient may be determined to be legally blind, total blindness is rare.  Most patients with advanced ARMD are able to ambulate and retain independence.

By Scott E Pautler, MD 

For a telemedicine consultation with Dr Pautler, please send email request to spautler@rvaf.com. We accept Medicare and most insurances in Florida. Please include contact information (including phone number) in the email. We are unable to provide consultation for those living outside the state of Florida with the exception of limited one-time consultations with residents of the following states: Alabama, Arkansas, Connecticut, Georgia, Minnesota, and Washington.

Copyright  © 2021-2022 Designs Unlimited of Florida.  All Rights Reserved. 

Serine and MacTel

What is MacTel?

MacTel (Macular Telangiectasia) is a degeneration of the center of the retina (called the macula) that affects central vision. The macula is a type of nerve tissue that works to give sharp central vision to read and see fine details. There is evidence that an amino acid called serine plays a role in the cause MacTel.1

How does serine relate to MacTel?

Serine is an amino acid that is used by the body to build proteins and lipids. If this building block is not used properly by the body, abnormal nerve lipids (deoxysphingolipids) may accumulate and damage nerve cells.

 In an inherited condition (hereditary sensory and autonomic neuropathy type 1) an abnormal enzyme causes abnormal nerve lipids in the body and can cause nerve damage. Peripheral nerve damage may cause numbness and tingling of the hands and feet. Autonomic nerve damage may interfere with internal organ function (e.g. intestines, bladder, heart). In addition, these patients frequently develop MacTel.  

Even without this inherited condition of neuropathy, patients with MacTel often have low blood levels of serine that result in high blood levels of abnormal nerve lipids. These abnormal nerve lipids have been shown to damage retinal cells and likely play a role in loss of vision in MacTel.

 What can be done with this information?

At present (1-2020) the authors of the research paper advise against starting treatment based on their paper. They caution that more research is needed. However, the FDA found that over-the-counter L-serine supplements to be generally safe. One study found the use of L-serine (400mg/kg/day) safely lowered the abnormal nerve lipids in a case of hereditary sensory and autonomic neuropathy.Side effects of taking L-serine include stomach discomfort, diarrhea, constipation, and frequent urination. Most supplements come in the form of capsules containing L-serine 500mg. It is unknown what dosage might be most effective for MacTel. A patient may wish to take the dosage recommended on the bottle by the manufacturers.

Check for current prices of L-serine on Amazon.

Another option is the use of fenofibrate, a prescription medication that can lower the abnormal nerve lipid levels. This option may be especially useful in patients with MacTel who have abnormal cholesterol and/or triglycerides because fenofibrate has already been approved for use in the treatment of these conditions apart from potential benefit for MacTel. 

In general, patients with MacTel who also have symptoms of sensory or autonomic neuropathy should notify their retinal specialist and internist for additional testing and consider treatment.

By Scott E. Pautler, MD

For a telemedicine consultation with Dr Pautler, please send email request to spautler@rvaf.com. We accept Medicare and most insurances in Florida. Please include contact information (including phone number) in the email. We are unable to provide consultation for those living outside the state of Florida with the exception of limited one-time consultations with residents of the following states: Alabama, Arkansas, Connecticut, Georgia, Minnesota, and Washington.

References:

1. Gantner, et al. Serine and lipid metabolism in macular disease and peripheral neuropathy. N Eng J Med 2019;10:1422-1433.

2. Auranen et al. Clinical and metabolic consequences of L-serine supplementation in hereditary sensory and autonomic neuropathy type 1C. Cold Spring Herb Case Stud 2017;3:6.

Please note: As an Amazon Associate I may earn from qualifying purchases.  You pay no additional fees by accessing the link.  These funds help defray the costs of maintaining this website. Thank you.

Pentosan (Elmiron) and Your Eyes

See Anatomy of the Eye

What side effects can pentosan polysulfate have on my eyes?

Although pentosan polysulfate (PPS) is of proven benefit for interstitial cystitis, it may cause damage to the eyes.  Early symptoms may be subtle.  Blurred vision, especially with reading, is common.  Straight lines may appear wavy or distorted.  There may be a slow adaptation from light to dark environments.  Blind spots or missing areas may occur in the central vision.  These symptoms are due to retinal damage; however, they are not specific to pentosan polysulfate damage.  The Eye MD (retina specialist) must use special tests to determine whether vision symptoms are due to pentosan polysulfate or other types of retinal conditions such as macular degeneration.    

Who is at risk of losing vision?

Ocular side effects appear to be related to a build-up of medicine in the body over years.  The longer a person has been on PPS, the greater the chances of developing retinal damage.  Although the average duration of use at the time of diagnosis is 15 years, some patients develop symptoms as early as three years after starting the medication.  With continued use of PPS, additional permanent damage occurs that may result in loss of vision.

What can I do to protect myself?

Pentosan polysulfate is an effective medication for control of pain with interstitial cystitis.  However, it is important to monitor your eyes for side effects that might indicate the need to stop the medication.  The Amsler grid chart should be checked at least once a week testing each eye separately, using glasses if needed.  Look for a missing part of the grid either above or below the central dot while looking only at the center of the grid.  Additionally, your Eye MD should examine your eyes every year with specific testing to look for early signs of retinal changes.  It may be useful to see a retinal specialist who has training in this area.

What happens if I develop retinal changes from pentosan polysulfate?

If early retinal changes are found, pentosan polysulfate may be discontinued.  By discontinuing pentosan polysulfate at an early stage, vision may be saved.  Continued examination is important to monitor the eyes for further changes.  There is no specific treatment for retinal toxicity from pentosan polysulfate. However, if blood vessels grow under the retina, treatment may be helpful as with wet macular degeneration.

By Scott E. Pautler, MD

For a telemedicine consultation with Dr Pautler, please send email request to spautler@rvaf.com. We accept Medicare and most insurances in Florida. Please include contact information (including phone number) in the email. We are unable to provide consultation for those living outside the state of Florida with the exception of limited one-time consultations with residents of the following states: Alabama, Arkansas, Connecticut, Georgia, Minnesota, and Washington.

Copyright  © 2019-2022 Designs Unlimited of Florida. All Rights Reserved.